Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.45 |
| ▸ | PPARA | Q07869 | 14/20 | 0.42 |
| ▸ | PPARD | Q03181 | 8/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7855547 | 1.00 | PPARG (0.45) | PPARGPPARAPPARDFAAHITGB3 | |
| SCHEMBL7851898 | 0.93 | PPARG (0.51) | PPARGPPARAPPARD | |
| SCHEMBL7851899 | 0.93 | PPARG (0.51) | PPARGPPARAPPARD | |
| SCHEMBL7843860 | 0.91 | PPARG (0.49) | PPARGPPARAPPARD | |
| SCHEMBL7843858 | 0.91 | PPARG (0.49) | PPARGPPARAPPARD | |
| SCHEMBL7855863 | 0.91 | PPARG (0.51) | PPARGPPARAPPARD | |
| SCHEMBL7852902 | 0.91 | PPARG (0.48) | PPARGPPARAPPARD | |
| SCHEMBL7851931 | 0.91 | PPARG (0.50) | PPARGPPARAPPARDITGB3ITGB1 | |
| SCHEMBL7851926 | 0.91 | PPARG (0.50) | PPARGPPARAPPARDITGB3ITGB1 | |
| SCHEMBL7843313 | 0.88 | PPARG (0.48) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6300339-B1 | USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE | NOVO NORDISK A/S (DK) | 2001-10-09 | — | — | US | claimed |
| EP-1123292-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | claimed |
| WO-2000023445-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | claimed |
| US-6300339-B1 | USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE | NOVO NORDISK A/S (DK) | 2001-10-09 | — | — | US | disclosed |
| EP-1123292-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023445-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |